CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOACaptura de pantalla 2022 09 14 a las 10.27.10    

Virus-Cell interaction. The ASFV model

Research summary:

African swine fever (ASF) is a devastating disease affecting both wild boar and domestic pigs. An outbreak in the Caucasus in 2007 started its spread across Russia and Eastern Europe, currently affecting Ukraine, Belarus, Poland, the Baltic States, the Czech Republic, Hungary, Moldova, Bulgaria and Romania. In August 2018 outbreaks in Belgium and China were reported, which represent dramatic extensions of the geographic distribution of ASF and further elevates the threat to the global swine industry. This situation makes imperative to improve our knowledge to make defensive tools against this important pathogen. The ASFV genome encodes many genes which are not essential for virus replication but are known to control host immune evasion, such as NFκB and the NFAT regulator A238L, the apoptosis inhibitor A224L, the viral homologous to cellular CD2, which mediates hemadsorption and AP-1 regulation, and several genes modulating the IFN synthesis in the infected cell. These genes are hypothesized to be involved in the natural attenuation of the genotype I parental ASFV NH/P68. Our group is currently spending efforts to build live attenuated vaccines (LAV) prototypes, by constructing recombinant viruses both from the naturally attenuated NH/P68 and from the virulent, presently circulating in Europe and China Armenia/07. The recombinant prototypes, lacking several of selected specific genes, have been generated mainly by using CRISPR technology and plate selection. Modified, naturally attenuated ASFV NH/P68 strain, produced in porcine alveolar macrophages (PAM) was used to vaccinate pigs that were protected against both homologous (genotype I) Lisbon 60 (L60) and heterologous Armenia/07 (genotype II). The recombinant viruses carrying specific deletions were all fully protective against parental L60 and only slightly protective against the heterologous circulating Armenia07 strain. Furthermore, our results suggested that apart from the viral skills acting to evade the immune system, lack of protection should be likely related to the cell line used to generate the vaccine; therefore, identifying a bottleneck that will compromise the safe commercial production of efficacious LAVs. In this regard, we have recently established several cell lines that can be potentially used to produce ASFV vaccines, which include COS-7 cells (only for virulent strains) and modified WSL, (a wild boar-derived lung cell line), which can be useful alternatives to the macrophage, the natural target of the infection in vivo.


Figure 1. Simplified overview of the IFN signalling pathways putatively counteracted by ASFV, focus on the cGAS-STING and JAK/STAT pathways.


Figure 2. Recombinant ASFV-GFP generated by CRISPR-Cas9 technology isolated by plaque assay.


* For external calls please dial 34 91196 followed by the extension number
Last nameNameLaboratoryExt.*e-mailProfessional category
Flores SimónCecilia2254589cflores(at)cbm.csic.esM2
Gata de BenitoJulia2254598julia.gata(at)cbm.csic.esTitulado Sup. Actividades Tecn. y Prof.GP1
Pérez NúñezDaniel2254598daniel_perez(at)cbm.csic.esDoctor FC1
Piredda Roberta2254598rpiredda(at)cbm.csic.esInvestigador Indef. GP1
Revilla NovellaYolanda2254570yrevilla(at)cbm.csic.esE. Investigadores Científicos de Organismos Públicos
Vigara AstilleroGonzalo2254598gvigara(at)cbm.csic.esM3 Predoc.formación

Relevant publications:

Participation in R&D and Innovation projects:

  • Validación de dianas farmacológicas neuroinflamatorias para el tratamiento del dolor crónico. INFLAPAIN Yolanda Revilla Novella. (CBMSO-CSIC-UAM). 01/11/2018- 04/02/2021. 245 €.
  • Desarrollo de compuestos terapéuticos basados en los sitios moleculares de interacción entre la proteína viral A238L y los complejos transcripcionales que regulan la síntesis de mediadores proinflamatorios y tumorales Yolanda Revilla Novella. (Fundación Ramón Areces). 02/03/2017-01/02/2020. 110 €.
  • Novel Vaccine Approaches against ASFV CEEZAD. Yolanda Revilla Novella. (CBMSO-CSIC KSU). 06/11/2014-12/03/2019. 200 €.
  • Nuevas Herramientas de Diagnostico y Desarrollo de Vacunas. BIO2013-46605-R Yolanda Revilla Novella. (Centro de Biología Molecular Severo Ochoa). 02/01/2014- 31/12/2016. 140.000 €.
  • Novel vaccine approaches against African Swine Fever Virus CEEZAD Funded Research. Yolanda Revilla Novella (Centro de Biología Molecular Severo Ochoa). 2014-2016. 61,5 €.
  • Targeted research effort on African swine fever. ASFORCE U.E. (Seventh Framework Programme). Yolanda Revilla Novella. (Centro de Biología Molecular Severo Ochoa). 2013-2016. 225.847 €.
  • Molecular mechanisms of virus-host interaction Ministerio de Educación y Ciencia (BFU2010-17794). Yolanda Revilla Novella. (Centro de Biología Molecular Severo Ochoa). 2010-2013. 120.000 €.
  • Evaluating and controlling the risk of African swine fever in the EU. ASFRISK. U.E. (Seventh Framework Programme). Ángel López Carrascosa/ Yolanda Revilla Novella. (Centro de Biología Molecular Severo Ochoa). 2008-2011. 297.000 €.
  • Procesos celulares modulados por virus y generación de nuevos productos antivirales. (el modelo del VPPA). Ministerio de Educación y Ciencia (BFU2007-63110). Yolanda Revilla Novella. (Centro de Biología Molecular Severo Ochoa). 2007-2010. 146.000 €.

Participation in R&D and Innovation contracts:

  • Development of new tools for ASFV vaccine Laboratorios Hipra, S.A. Yolanda Revilla Novella. 14/10/2019-14/10/2023. 170.000 €.
  • ASFV Vaccine Development CAHEC (Center Animal Health Emerging China). Yolanda Revilla Novella. 03/12/2018-P2Y. 210 €.
  • ASFV Tet on Vaccine development Neotech CDTI. Yolanda Revilla Novella. 12/12/2017-P3Y. 134 €
  • Sardinian strain ASFV vaccine development. Universitá de Sassari-CBMSO Yolanda Revilla Novella. 16/11/2017-P3Y.66 €

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand


What are cookies?

A cookie is a file that is downloaded to your computer when you access certain web pages. Cookies allow a web page, among other things, to store and retrieve information about the browsing habits of a user or their equipment and, depending on the information they contain and the way they use their equipment, they can be used to recognize the user.

Types of cookies

Classification of cookies is made according to a series of categories. However, it is necessary to take into account that the same cookie can be included in more than one category.

  1. Cookies according to the entity that manages them

    Depending on the entity that manages the computer or domain from which the cookies are sent and treat the data obtained, we can distinguish:

    • Own cookies: those that are sent to the user's terminal equipment from a computer or domain managed by the editor itself and from which the service requested by the user is provided.
    • Third party cookies: those that are sent to the user's terminal equipment from a computer or domain that is not managed by the publisher, but by another entity that processes the data obtained through the cookies. When cookies are installed from a computer or domain managed by the publisher itself, but the information collected through them is managed by a third party, they cannot be considered as own cookies.

  2. Cookies according to the period of time they remain activated

    Depending on the length of time that they remain activated in the terminal equipment, we can distinguish:

    • Session cookies: type of cookies designed to collect and store data while the user accesses a web page. They are usually used to store information that only is kept to provide the service requested by the user on a single occasion (e.g. a list of products purchased).
    • Persistent cookies: type of cookies in which the data is still stored in the terminal and can be accessed and processed during a period defined by the person responsible for the cookie, which can range from a few minutes to several years.

  3. Cookies according to their purpose

    Depending on the purpose for which the data obtained through cookies are processed, we can distinguish between:

    • Technical cookies: those that allow the user to navigate through a web page, platform or application and the use of different options or services that exist in it, such as controlling traffic and data communication, identifying the session, access to restricted access parts, remember the elements that make up an order, perform the purchase process of an order, make a registration or participation in an event, use security elements during navigation, store content for the broadcast videos or sound or share content through social networks.
    • Personalization cookies: those that allow the user to access the service with some predefined general characteristics based on a series of criteria in the user's terminal, such as the language, the type of browser through which the user accesses the service, the regional configuration from where you access the service, etc.
    • Analytical cookies: those that allow the person responsible for them to monitor and analyse the behaviour of the users of the websites to which they are linked. The information collected through this type of cookies is used in the measurement of the activity of the websites, applications or platforms, and for the elaboration of navigation profiles of the users of said sites, applications and platforms, in order to introduce improvements in the analysis of the data of use made by the users of the service.

Cookies used on our website

The CBMSO website uses Google Analytics. Google Analytics is a simple and easy to use tool that helps website owners to measure how users interact with the content of the site. You can consult more information about the cookies used by Google Analitycs in this link.

Acceptance of the Cookies Policy

The CBMSO assumes that you accept the use of cookies if you continue browsing, considering that it is a conscious and positive action from which the user's consent is inferred. In this regard, you are previously informed that such behaviour will be interpreted that you accept the installation and use of cookies.

Knowing this information, it is possible to carry out the following actions:

  • Accept cookies: if the user presses the acceptance button, this warning will not be displayed again when accessing any page of the portal.
  • Review the cookies policy: the user can access to this page in which the use of cookies is detailed, as well as links to modify the browser settings.

How to modify the configuration of cookies

Using your browser you can restrict, block or delete cookies from any web page. In each browser the process is different, here we show you links on this particular of the most used browsers: